AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BLCO · NYSE · Medical - Instruments & Supplies

Bausch + Lomb

Makes contact lenses, eye-care products, ophthalmic medicines, and surgical tools.

$17.15

After-hours close0.00 (0.00%)

At close$17.15(+0.12%)

Something off on this page? Send us feedback.

Profile

Bausch + Lomb CorporationBLCOHealth Care

Sells contact lenses, lens-care and over-the-counter eye-care products, ophthalmic medicines, and surgical equipment. The portfolio is organized around eye health, operates internationally, and remains a majority-controlled subsidiary of Bausch Health.

Products span contact lenses, lens care, and over-the-counter eye-care products, alongside ophthalmic medicines and surgical devices and instruments. The integrated portfolio serves vision care, pharmaceutical, and surgical uses across international markets. Its offerings are intended to address eye-health needs across different stages of life.

Founded in 1853, the business grew from optical goods into eye health through soft contact lenses, lens-care brands, ophthalmic pharmaceuticals, and surgical capabilities. It operates through a broad product portfolio rather than a single-category franchise.

Bausch Health retains controlling ownership, so the company remains a subsidiary despite its NYSE listing.

Company facts

CEOBrent Saunders

ListedMay 6, 2022

ExchangeNYSE

HeadquartersVaughan, Canada

CountryCanada

Employees13,500

CIK0001860742

ISINCA0717051076

Key statistics

Market cap$6.13B

EPS (ttm)−$0.4782

P/E (ttm)−35.86

ROE-2.7%

P/B0.9605

P/S1.15

Dividend yield—

Beta1.02vs XLV 0.75

Year to date +3.4% · Average volume (30d) 416.4K

Analysts

Price target, next 12 months$19.00+10.8%Median of 17 analysts · vs the Aug 28 close

ConsensusBuy8 of 17 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $17.15

High$23.00+34.1%

Median$19.00+10.8%

Low$16.00−6.7%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 3, 2026	H.C. Wainwright	Reiterate	Buy	$20	$21
Jul 30, 2026	UBS	Reiterate	Buy	$21	$23
Jul 28, 2026	UBS	Initiate	Buy		$21
Jul 6, 2026	Evercore ISI	Target		$18	$17
Apr 30, 2026	Deutsche Bank	Target		$18	$16

Earnings

EPS

Estimate$0.21

ReportedDue Nov 4, 2026

Revenue

Estimate$1.37B

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 29, 2026Q2 FY26	$0.15	$0.16	+3.6%	$1.37B	$1.39B	+1.8%	+4.88%
Apr 29, 2026Q1 FY26	$0.06	$0.08	+33.3%	$1.22B	$1.24B	+2.3%	+3.65%
Feb 18, 2026Q4 FY25	$0.35	$0.32	−8.6%	$1.39B	$1.41B	+1.4%	−0.11%
Oct 29, 2025Q3 FY25	$0.16	$0.18	+12.5%	$1.38B	$1.28B	−7.4%	−2.13%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$1.14B	$1.28B	$1.28B	$1.41B	$1.24B	$1.39B
Gross profit	$588.0M	$686.0M	$703.0M	$816.0M	$704.0M	$821.0M
Operating income	−$61.0M	$11.0M	$80.0M	$158.0M	$59.0M	$83.0M
Net income	−$212.0M	−$62.0M	−$28.0M	−$58.0M	−$71.0M	−$14.0M
Diluted EPS	−$0.60	−$0.18	−$0.08	−$0.16	−$0.20	−$0.04
Gross margin	51.7%	53.7%	54.9%	58.1%	56.6%	59.1%
Operating margin	-5.4%	0.9%	6.2%	11.2%	4.7%	6.0%

Fiscal years (4-quarter sums)FY21 $3.77B · FY22 $3.77B · FY23 $4.15B · FY24 $4.79B · FY25 $5.10B

Revenue by product · Q2 FY26

Device Products$524.0M · 38%

Over The Counter Products$497.0M · 36%

Pharmaceutical Products$300.0M · 22%

Branded And Other Generic Products$68.0M · 5%

Other Revenues$5.0M · 0%

Revenue by geography · FY25

United States And Puerto Rico$2.55B · 53%

Other Countries$777.0M · 16%

China$358.0M · 7%

France$246.0M · 5%

Japan$186.0M · 4%

Germany$164.0M · 3%

Canada$135.0M · 3%

Italy$102.0M · 2%

Spain$101.0M · 2%

Mexico$75.0M · 2%

Poland$75.0M · 2%

Korea, Republic of$51.0M · 1%

Balance sheet, Jun 30, 2026Cash & short-term investments $367.0M · Total debt $5.12B · Total assets $13.86B · Shareholders' equity $6.38B

Dividends

No dividends on record.

Ownership

Institutions 10.63%37.97M sharesInsiders 0.89%3.16M sharesOther 88.48%316.03M shares

Shares outstanding 357.17M · Float 45.55M · 12.8% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Deutsche Bank AG\	3.53M	0.99%	13F	May 6, 2026
Icahn Carl C	3.50M	0.98%	13F	May 15, 2026
Oaktree Capital Management LP	3.38M	0.95%	13F	May 20, 2026
D. E. Shaw & Co., Inc.	3.15M	0.88%	13F	May 15, 2026
Goldentree Asset Management LP	2.66M	0.74%	13F	May 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 10, 2026	Frederick Munsch	officer: SVP, Controller and CAO	−52,900	$16.78
Aug 7, 2026	Andrew C. von Eschenbach	director	−6,059	$16.58
Aug 6, 2026	Andrew C. von Eschenbach	director	−12,500	$16.50
Mar 6, 2026	Brent L. Saunders	director, officer: CEO and Chairman of the Board	+14,700	$17.14
Mar 6, 2026	Sam Eldessouky	officer: EVP and CFO	+4,000	$17.13